Tonix Pharmaceuticals Holding Corp. (TNXP) has emerged as a notable name in the biopharmaceutical space with recent clinical updates, strategic partnerships, and regulatory progress. The company's expanding pipeline and active engagement with leading research institutions position it for continued visibility in the healthcare sector.
Phase 2 Study of TNX-1500 in Kidney Transplant
On November 4, Tonix announced a collaboration with Massachusetts General Hospital (MGH) to initiate a Phase 2 clinical trial evaluating TNX-1500, a monoclonal antibody targeting CD40L, in kidney transplant recipients. The study aims to assess safety and activity while reducing reliance on conventional immunosuppressive therapies, which are associated with significant side effects.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.